EGFR and non-small cell lung carcinoma: Similarly, other EGFR-TKIs, such as erlotinib [38] and osimertinib [39], exhibited a higher frequency of drug-induced pneumonitis during molecular-targeted therapies in NSCLC with comorbid IP compared with those without IP.